---
title: Dipharma vs SEQENS
slug_a: dipharma
slug_b: seqens
site: cdmo
review_signal_gate: closed
canonical_path: /compare/dipharma/seqens
generated_by: BioBM Editorial AI
---

# Dipharma vs SEQENS

This comparison is auto-generated by BioBM Editorial AI and intended as an evidence-oriented side-by-side reference.

## Company A

Dipharma (dipharma) is listed for cdmo. Global CDMO and API manufacturer with 600 employees, 4 cGMP plants, and 75+ years of experience in hazardous chemical synthesis, offering exclusive synthesis services and catalogue APIs with FDA, AIFA, and PMDA inspections since 1970.

Services: 6. Modalities: 1. Indications: 0. Locations: 3. Certifications: 0. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (6).

Review summary: Review summary withheld until site-level review gate opens.

## Company B

SEQENS (seqens) is listed for cdmo. Global CDMO and specialty ingredients manufacturer with 16 production sites and 9 R&D centres offering custom development and GMP manufacturing of pharmaceutical APIs, intermediates, and specialty chemicals from preclinical to commercial scale.

Services: 8. Modalities: 1. Indications: 0. Locations: 15. Certifications: 9. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in locations (15).

Review summary: Review summary withheld until site-level review gate opens.